文献速递创伤骨科骨质疏松与代谢性骨病

特立帕肽与骨盆骨折愈合:一项2期随机对照试验

Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial.
PubMed 文献 · Osteoporos Int · 2021-08-12

本研究将骨盆骨折患者随机分组,盲法每日皮下注射特立帕肽(TPTD)或安慰剂,评估3个月内的愈合与功能结局。结果显示,TPTD组在CT愈合或疼痛减轻方面无改善证据,但身体功能表现有改善而安慰剂组无改善(组间差异p<0.03)。

要点

  • 特立帕肽20μg/日未改善骨盆骨折3个月时的CT骨皮质桥接愈合。
  • 两组疼痛评分均显著下降,但无组间差异。
  • 特立帕肽组CSPPS和TUG改善,安慰剂组无改善,组间差异p<0.03。

核心结论

  • 在小型随机盲法研究中,特立帕肽与安慰剂相比未改善3个月时CT显示的放射学愈合或疼痛,但特立帕肽组身体功能表现改善而安慰剂组未显现。

研究设计与样本

  • 随机、安慰剂对照研究纳入35例50岁以上女性与男性骨盆骨折患者,骨折后4周内入组,盲法每日皮下注射特立帕肽20μg或安慰剂,评估3个月。

主要发现

  • 意向性治疗分析显示两组骨皮质桥接评分无组间差异,特立帕肽组50%骨折愈合而安慰剂组53%愈合,校正年龄、骶骨骨折和骨折移位后不变。
  • 两组中位疼痛评分均显著下降,无组间差异。
  • 特立帕肽组CSPPS和TUG改善而安慰剂组无改善,CSPPS在2个月和3个月组间差异p<0.03。

关键数值与推荐

  • 骨折愈合采用CT图像5点量表评估骨皮质桥接,基线及3个月评估。
  • 疼痛采用数字评定量表每月评估。
  • 身体功能采用连续总结身体表现评分(基于4米步行速度、计时重复坐立和平衡)及计时起立行走测试每月评估。

临床怎么用

  • 对于骨盆骨折患者,特立帕肽20μg/日可能改善身体功能表现,但不应期望其促进放射学愈合或减轻疼痛。

局限性

  • 样本量小(35例),研究期限仅3个月,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Pelvic fracture patients were randomized to blinded daily subcutaneous teriparatide (TPTD) or placebo to assess healing and functional outcomes over 3 months. With TPTD, there was no evidence of improved healing by CT or pain reduction; however, physical performance improved with TPTD but not placebo (group difference p < 0.03). INTRODUCTION: To determine if teriparatide (20 μg/day; TPTD) results in improved radiologic healing, reduced pain, and improved functional outcome vs placebo over 3 months in pelvic fracture patients. METHODS: This randomized, placebo-controlled study enrolled 35 patients (women and men >50 years old) within 4 weeks of pelvic fracture and evaluated the effect of blinded TPTD vs placebo over 3 months on fracture healing. Fracture healing from CT images at 0 and 3 months was assessed as cortical bridging using a 5-point scale. The numeric rating scale (NRS) for pain was administered monthly. Physical performance was assessed monthly by Continuous Summary Physical Performance Score (based on 4 m walk speed, timed repeated chair stands, and balance) and the Timed Up and Go (TUG) test. RESULTS: The mean age was 82, and >80% were female. The intention to treat analysis showed no group difference in cortical bridging score, and 50% of fractures in TPTD-treated and 53% of fractures in placebo-treated patients were healed at 3 months, unchanged after adjustment for age, sacral fracture, and fracture displacement. Median pain score dropped significantly in both groups with no group differences. Both CSPPS and TUG improved in the teriparatide group, whereas there was no improvement in the placebo group (group difference p < 0.03 for CSPPS at 2 and 3 months). CONCLUSION: In this small randomized, blinded study, there was no improvement in radiographic healing (CT at 3 months) or pain with TPTD vs placebo; however, there was improved physical performance in TPTD-treated subjects that was not evident in the placebo group.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Nieves JW, Cosman F, McMahon D, et al. Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial. Osteoporos Int. 2021. PMID: 34383100. doi:10.1007/s00198-021-06065-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。